Clinical Trials | A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

The University of Virginia is seeking women aged 18 and older to participate in a clinical trial. You may be eligible if you have recurrent or progressive endometrial cancer following prior cancer treatment. This study will evaluate an investigational medication called Rina-S (GEN1184) compared to standard-of-care treatment selected by your physician (either paclitaxel or doxorubicin). If you take part in this study, you will be randomized (assigned by chance) with an equal likelihood (50:50) of receiving either Rina-S or your physician’s choice of treatment (paclitaxel or doxorubicin). All study medications are given through intravenous (IV) infusion and will be evaluated for how well they treat recurrent or progressive endometrial cancer after previous therapies. This study will include: blood draws, electrocardiograms (ECGs), echocardiograms (ECHO) or multigated acquisition (MUGA), tumor imaging assessments, questionnaires, and physical examinations. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. More information can be found here: https://clinicaltrials.gov/study/NCT07166094